Algorae Pharmaceuticals Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2016 - 2020
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	2016 - 2020
Net Income	-0.8	-2.1	-2.11	-1.96	-1.46	Upgrade
Depreciation & Amortization	-	-	0	0	0.05	Upgrade
Loss (Gain) From Sale of Assets	-	0	-	0.01	-	Upgrade
Loss (Gain) From Sale of Investments	-	-	-	-	-0.11	Upgrade
Stock-Based Compensation	0.04	0.77	0	-0.04	-0.05	Upgrade
Other Operating Activities	-0.01	0.01	0.02	-0.01	0	Upgrade
Change in Accounts Receivable	0.01	0.05	-0.07	-0.02	0.09	Upgrade
Change in Accounts Payable	-0.02	-0.18	0.16	0.03	-0.03	Upgrade
Change in Other Net Operating Assets	0.01	-0.09	0.01	-0.05	0.04	Upgrade
Operating Cash Flow	-0.79	-1.52	-1.99	-2.04	-1.46	Upgrade
Capital Expenditures	-	-	-	-0	-	Upgrade
Investment in Securities	0.45	-0.28	0.98	-	0.11	Upgrade
Other Investing Activities	-	-	-	0.04	-	Upgrade
Investing Cash Flow	0.45	-0.28	0.98	0.04	0.11	Upgrade
Long-Term Debt Repaid	-	-	-	-	-0.04	Upgrade
Net Debt Issued (Repaid)	-	-	-	-	-0.04	Upgrade
Issuance of Common Stock	-	0.57	2.15	5.15	-	Upgrade
Other Financing Activities	-0	-0.05	-0.3	-0.46	-	Upgrade
Financing Cash Flow	-0	0.52	1.85	4.69	-0.04	Upgrade
Foreign Exchange Rate Adjustments	-0	-0	0.01	-0.01	0	Upgrade
Net Cash Flow	-0.34	-1.28	0.85	2.67	-1.4	Upgrade
Free Cash Flow	-0.79	-1.52	-1.99	-2.05	-1.46	Upgrade
Free Cash Flow Margin	-556.72%	-1216.69%	-4727.46%	-60088.31%	-544.97%	Upgrade
Free Cash Flow Per Share	-	-0.00	-0.00	-0.00	-0.00	Upgrade
Levered Free Cash Flow	-0.55	-0.48	-0.78	-1	-0.73	Upgrade
Unlevered Free Cash Flow	-0.55	-0.48	-0.78	-1	-0.73	Upgrade
Change in Working Capital	-0	-0.21	0.1	-0.04	0.1	Upgrade

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.